Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marc Tessier-Lavigne leaves Pfizer board

This article was originally published in Scrip

Executive Summary

Dr Marc Tessier-Lavigne has stepped down from Pfizer's board of directors – effective 14 May 2015. His decision is coincident with the launch of Denali, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases. Dr Tessier-Lavigne is a co-founder of Denali, and he will serve as chair of the company. Dr Tessier-Lavigne was appointed to Pfizer's board in December 2011, and most recently he was a member of the regulatory and compliance committee and science and technology committee.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC028783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel